Aviceda Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.avicedarx.com
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
Phase 2
Terminated
- Conditions
- Diabetic RetinopathyDiabetic Macular Edema
- Interventions
- Drug: AVD-104
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Aviceda Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06181227
- Locations
- 🇺🇸
Erie Retina Research, Erie, Pennsylvania, United States
🇺🇸Texas Retina Associates, Dallas, Texas, United States
🇺🇸West Texas Retina Consultants, Wichita Falls, Texas, United States
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Phase 2
Active, not recruiting
- Conditions
- Geographic Atrophy of the MaculaMacular Degeneration
- Interventions
- Drug: AVD-104Drug: Avacincaptad
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Aviceda Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05839041
- Locations
- 🇺🇸
Associated Retina Consultants, Scottsdale, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
© Copyright 2025. All Rights Reserved by MedPath